Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 mai 2015 12h46 HE | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease (EVD)

PHILADELPHIA, May 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European Medicines Agency (EMA) has published on May 22,...
20 mai 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx to Present at the Marcum Microcap Conference in New York

PHILADELPHIA, May 20, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) will present at the Marcum Microcap Conference being held at the Grand Hyatt Hotel in New York City on Wednesday, May...
13 mai 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2015

PHILADELPHIA, May 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2015. The net loss (including non-cash effects)...
11 mai 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A.,...
28 avr. 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Midtown Partners & Co, LLC Initiates Coverage and Arrowhead b.i.d. Issues Coverage Update on Hemispherx Biopharma

PHILADELPHIA, April 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") reported today that Midtown Partners &Co, LLC initiates coverage of...
24 mars 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

PHILADELPHIA, March 24, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European subsidiary, "Hemispherx Biopharma Europe...
23 mars 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus

PHILADELPHIA, March 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") will present integrated findings of new studies of Ampligen®...
20 mars 2015 09h28 HE | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2014

PHILADELPHIA, March 20, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the year ended December 31, 2014. The net loss (including non-cash effects) was...
09 mars 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx Enters a Collaboration with Emerge Health for the Commercialization of Ampligen for Chronic Fatigue Syndrome (CFS) in Australia and New Zealand

PHILADELPHIA, March 9, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Emerge Health Pty Ltd....
02 mars 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces the Completion of the Newly Upgraded Alferon(R) Facility: Commercial Production of Alferon(R) is in the Final Stage Integrating Continuous Flow Manufacturing Technology

PHILADELPHIA, March 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced today that its manufacturing site located in New Brunswick, New...

Page précédente